Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Treilleux

Showing results (71-80 of 186) with videos related to

Pageof 19
Sort By:
Gynecologic Oncology|October 26, 2013
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO networkDenis Maillet, Thibaut Goulvent, Ruth Rimokh, et al.
International Journal of Cancer|April 5, 2013
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitorPaul Vilquin, Marie Villedieu, Evelyne Grisard, et al.
Endocrine-Related Cancer|May 18, 2022
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cellsRazan Abou Ziki, Romain Teinturier, Yakun Luo, et al.
Cancer Research|January 14, 2018
Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10Adrien Nougarede, Nikolay Popgeorgiev, Loay Kassem, et al.
Breast Cancer Research and Treatment|September 25, 2021
Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypesRomain Teinturier, Razan Abou Ziki, Loay Kassem, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinomaHiroyuki Fujiwara, Harushige Yokota, Bradley Monk, et al.
Molecular Oncology|June 29, 2014
A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancersNhan T Nguyen, Julie A Vendrell, Coralie Poulard, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 29, 2025
Mucinous ovarian carcinoma: Impact of ovarian stimulation, hormonal contraception, and hormone replacement therapyChloé Barbier de Reulle, Marine Rebotier, Nicolas Chopin, et al.
Histopathology|June 3, 2015
DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group studyThibault Goulvent, Isabelle Ray-Coquard, Stéphane Borel, et al.
Bulletin Du Cancer|September 7, 2023
Gynecological carcinosarcomas: Overview and future perspectivesLaetitia Collet, Andrea María González López, Clémence Romeo, et al.
Pageof 19

Showing results (71-80 of 186) with videos related to

Sort By:
Pageof 19
Gynecologic Oncology|October 26, 2013
Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO networkDenis Maillet, Thibaut Goulvent, Ruth Rimokh, et al.
International Journal of Cancer|April 5, 2013
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitorPaul Vilquin, Marie Villedieu, Evelyne Grisard, et al.
Endocrine-Related Cancer|May 18, 2022
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cellsRazan Abou Ziki, Romain Teinturier, Yakun Luo, et al.
Cancer Research|January 14, 2018
Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10Adrien Nougarede, Nikolay Popgeorgiev, Loay Kassem, et al.
Breast Cancer Research and Treatment|September 25, 2021
Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypesRomain Teinturier, Razan Abou Ziki, Loay Kassem, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 25, 2014
Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinomaHiroyuki Fujiwara, Harushige Yokota, Bradley Monk, et al.
Molecular Oncology|June 29, 2014
A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancersNhan T Nguyen, Julie A Vendrell, Coralie Poulard, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|January 29, 2025
Mucinous ovarian carcinoma: Impact of ovarian stimulation, hormonal contraception, and hormone replacement therapyChloé Barbier de Reulle, Marine Rebotier, Nicolas Chopin, et al.
Histopathology|June 3, 2015
DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group studyThibault Goulvent, Isabelle Ray-Coquard, Stéphane Borel, et al.
Bulletin Du Cancer|September 7, 2023
Gynecological carcinosarcomas: Overview and future perspectivesLaetitia Collet, Andrea María González López, Clémence Romeo, et al.
Pageof 19